Neuroleptic Malignant Syndrome in a Patient with Succinic Semialdehyde Dehydrogenase Deficiency

P. Neu; S. Seyfert; J. Brockmöller; M. Dettling; P. Marx

doi:10.1055/s-2002-19830

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2002; 35(1): 26-28
DOI: 10.1055/s-2002-19830

Case Report

Neuroleptic Malignant Syndrome in a Patient with Succinic Semialdehyde Dehydrogenase Deficiency

P. Neu¹ , S. Seyfert² , J. Brockmöller³ , M. Dettling⁴ , P. Marx²

¹Department of Psychiatry, Freie Universität Berlin, Germany
²Department of Neurology, Freie Universität Berlin, Germany
³Department of Clinical Pharmacology, Charité, Humboldt Universität Berlin, Germany
⁴Department of Psychiatry, Charité, Humboldt Universität Berlin, Germany

Abstract

A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol. We investigated the patient's serum for all frequent polymorphisms in cytochrome P450 2D6, assuming him to be a poor neuroleptic metabolizer. We will also discuss other potential mechanisms inducing this disturbance and its differential diagnoses.

Full Text

References

1 Aicardi J. Diseases of the Nervous System in Childhood. 2nd edition. Cambridge; Mac Keith Press, University Press 1998
2 Boyd R D. Neuroleptic malignant syndrome and mental retardation: review and analysis of 29 cases. Am J Ment Retardation. 1993; 98 (3) 359
3 Denborough M. Malignant hyperthermia. Lancet. 1998; 352 1131-1136
4 Fink M. Neuroleptic Malignant Syndrome and Catatonia: One Entity or Two?. Biol Psychiatry. 1996; 39 1-4
5 Fink M. Toxic Serotonin Syndrome or Neuroleptic Malignant Syndrome?. Pharmacopsychiat. 1996; 29 159-161
6 Gibson K M, Christensen E, Jakobs C. The clinical phenotype of succinic semialdehyde dehydrogenase deficiency aciduria: case reports of 23 new patients. Pediatrics. 1997; 99 567-574
7 Gibson K M, Hoffmann G F, Hodson A K, Boiglieri T, Jakobs C. 4-Hydroxybutyric acid and the clinical phenotype of succinic semialdehyde dehydrogenase deficiency, an inborn error of GABA metabolism. Neuropediatrics. 1998; 29 (1) 14-22
8 Guerra R J. Sympathoadrenal Hyperactivity and the Etiology of Neuroleptic Malignant Syndrome. Am J Psychiatry. 1999; 156 169-180
9 Hardman J G, Limbird L E, Molinoff P B, Ruddon R W, Gilnian A G. The Pharmacological basic of therapeutics. 9th edition. New York; MacGraw-Hill 1995: 1143
10 Leonhard K. The Classification of Endogenous Psychoses, 5th ed. New York; Irvington 1979
11 Levenson J L. Neuroleptic malignant syndrome. Am J Psychiatry. 1985; 142 1137-1145
12 Mihara K, Suzuki A, Konto T, Yasui N, Furukori H, Nagashima U, Otani K, Kaneko S, Inoue Y. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol in Japanese patients with schizophrenia. Clin Pharmacol Ther. 1999; 65 (3) 291-294
13 Nisijima K, Ishiguro T. Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome. J Psychiat Res. 1995; 5/6 233-244
14 Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 Variants in a Caucasian Population: Allele Frequencies and Phenotypic Consequences. Am J Hum Genet. 1997; 60 284-295
15 Spina E, Ancione M, Di Rosa A E, Meduri M, Caputi A P. Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. Eur J Clin Pharmacol. 1992; 42 (3) 347-348

Dr. Peter Neu

Psychiatrische Poliklinik der FU Berlin

Eschenallee 3

14050 Berlin

Germany

Phone: + 49-30-8445-8673

Fax: + 49-30-8445-8388

Email: peter.neu@medizin.fu-berlin.de